OF JC VIRUS ACTIVATION AND PML (PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY) DURING IMMUNOSUPPRESSIVE THERAPY

FIELD OF THE INVENTION

[0001] The present invention relates to methods and compositions for eliminating John

Cunningham Virus (JCV) from host cells prior to and during the administration of immunosuppressive therapy, to eliminate the risk of activation of latent JCV, and the consequent onset of progressive multifocal leukoencephalopathy (PML). In particular, the invention relates to strategies for eliminating JCV by administration of compositions including Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated endonucleases, and one or more specific guide RNA sequences, to cleave target sites within the JCV genome. The invention also relates to strategies including the administration of JCV-targeting compositions including zinc-finger nucleases (ZFN), or transcription activator-like effector nucleases (TALEN).

BACKGROUND

[0002] Therapies have been developed to treat a wide range of formerly intractable diseases or conditions, such as multiple sclerosis; various cancers, autoimmune diseases such as Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis; and organ transplant rejection. A partial list of some of these therapies, and their mechanisms of action, is shown in TABLE 1. It can be seen, from TABLE 1, that these therapies cause immunosuppression either by inactivation, inhibition, or immobilization of immune effector cells (B-cells, T-cells, dendritic cells, monocytes, macrophages), or by cytotoxic side effects on immune effector cells.

TABLE 1. Drugs that have been shown to trigger JC Virus and result in PML:

Drug Treatment MOA

IMM UNOMODULATO S

Brentuximab vedotin Hodgkin's lymphomas anti-CD30

Rituximab B-cell cancers inhibits B-cell activity

anti-alpha-4 integrin. a4-integrin is

required for white blood cells to

Multiple Sclerosis and Crohn's

Natalizumab move into organs by preventing

Disease

their crossing of blood vessel walls

to reach affected organs

Fingolimod Multiple Sclerosis

Efalizumab Psoriasis inhibits lymphocyte activation

Vedolizumab ulcerative colitis and Crohn's Blocking the α4β7 integrin disease causes gut-selective antiinflammatory activity

psoriasis, necrobiosis lipoidica,

granuloma annulare,

Dimethyl fumarate hypoxic cell radiosensitizer

sarcoidosis, and Multiple

Sclerosis

IMM UNOSUPPRESSANTS

Belatacept immunosuppressant blocks T-cell activation

Calcineurin Inhibitors/T-cell

Tacrolimus immunosuppressant

inhibitors

Sirolimus immunosuppressant mTOR inhibitors

Glucocorticoids immunosuppressant steroids

Methotrexate immunosuppressant antimetabolites

Azathioprine immunosuppressant antimetabolites

Cyclosporine immunosuppressant T-cell inhibitors

Cyclophosphamide immunosuppressant alkylating agents

Chlorambucil immunosuppressant alkylating agents

Antiproliferative/antibiotic

Mycophenolate mofetil immunosuppressant

agent

Daclizumab immunosuppressant prevents T-cell activation

Crohn's disease, ulcerative

colitis, psoriasis, psoriatic

Infliximab anti-TNFoc

arthritis, ankylosing spondylitis,

and rheumatoid arthritis

[0003] The immunosuppressive action of these therapies carries the risk of activation of opportunistic pathogens that are normally kept in check by the immune system. Among the most serious risks is the risk of activation of John Cunningham Virus (JCV), a human neurotropic polyomavirus. JCV is the etiological agent of a fatal demyelinating disease, progressive multifocal leukoencephalopathy (PML). Lytic infection of JCV in glial cells of the central nervous system (CNS) results in the death of oligodendrocytes, the cells that are responsible for the production of myelin sheaths of neurons in the brain. This leads to a broad range of mild to severe neurological disturbances and eventually death (Berger, 2011). There are a number of predisposing factors to PML, all of which involve some level of impairment of the immune system.

[0004] Seroepidemological data indicate that the 75-80% of the human population is infected with JCV. Much of this infection occurs during childhood, by largely unknown routes (Saribas, et al., 2010). The virus typically remains latent, causing no symptoms. In a setting of impaired immunity, especially cellular immunity, the virus can reactivate, proliferating and inducing the symptoms of PML (Waggoner, et al, 2009). Latent virus can be maintained in the urinary tract and bone marrow, in the spleen and other lymphoid tissues, and in the CNS (Bayliss, et al., 2012). Reactivation during immunosuppression can reflect the reactivation of latent virus in the CNS, as well as the hematogenous spread of reactivated virus to the CNS (Bag, et al., 2010).

[0005] The JCV genome is comprised of double-stranded circular DNA of 5.1 kb in size, which codes for two classes of proteins at the early phase of viral infection, i.e. before DNA replication, and at the late phase of the infection cycle (DeCaprio, et al., 2013). A bi-directional coding sequence positioned between the early and late genes is responsible for viral gene expression and contains the origin of viral DNA replication. The viral early protein, large T-antigen (T-Ag), and a family of smaller sized T-Ag proteins, are produced by alternative splicing, and have a regulatory role in orchestrating the viral replication cycle. The large T-Ag, in particular, is responsible for initiation of viral DNA replication and the stimulation of viral late gene transcription, and thus is critical for all aspects of the viral life cycle (for review see White and Khalili, 2004). T-Ag binds to several cellular proteins such as p53 and pRb, and dysregulates proliferation of host cells. The late proteins include the viral capsid proteins VP1, VP2, and VP3 and a small regulatory protein known as agnoprotein (Khalili, et al., 2005).

[0006] Treatments for autoimmune disorders such as multiple sclerosis and rheumatoid arthritis, with new therapeutic immunomodulatory monoclonal antibodies, including natalizumab (Chakley and Berger, 2013) efalizumab (Schwab, et al., 2012), and rituximab Clifford, et al., 2011), are recognized as a predisposing factors for PML (Nagayama, et al., 2013). As a consequence of the risk of JCV activation and PML, these treatments, and many of the other treatments listed in Table 1, must to be administered in sub-optimal concentrations with extensive patient monitoring. In some cases, the PML risk is sufficient to cause the removal of immunosuppressive drugs from the market, thereby barring patient access to potentially life-saving treatments.

[0007] A number of treatment options have been applied to PML, largely without success

(Tavazzi, et al. 2012). Diverse approaches have targeted various points in the viral life cycle, such as cellular entry and replication. Since interaction between JCV and the serotonin 2A receptor (5-HT2AR) has been reported to be required for viral entry (Elphick, et al., 2004), risperidone, which binds 5HT2AR, has been tested but found to have no effect (Chapagain, et al., 2008). Small molecule inhibitors of viral replication such as cidofovir have been tested in vitro and in vivo, but have yielded conflicting results (Andrei, et al., 1997, Hou and Major, 1998). Alternative strategies are urgently required for dealing with this fatal demyelinating disease.

[0008] One potentially effective strategy would be to eliminate latent JCV from the host cells of patients prior to the start of immunosuppressive therapy, or during and after the course of therapy. With no latent virus to be activated, there would be no need to treat an active JCV infection. New and developing gene editing systems that target the JCV viral genome would be particularly attractive tools for JCV elimination. Example systems include zinc-finger nucleases (ZFN), transcription activator-like effector nucleases (TALEN) and Clustered Regulatory Interspaced Short Palindromic Repeat (CRISPR)- associated nuclease systems (Gaj, et al., 2013).

[0009] In particular, tools and techniques based on CRISPR/endonuclease DNA editing systems offer unprecedented control over genome editing (Mali, et al., 2013, Hsu, et al., 2014). The CRISPR/Cas9 (CRISPR-associated endonuclease 9) system was developed from the adaptive immune system of bacteria and archaea. The CRISPR/Cas9 system uses short guide RNAs (gRNAs) to direct the cleavage of specific nucleic acid target sequences by a Cas9 endonuclease (Bhaya, et al., 2011). The cleavage, usually a blunt ended double-strand cut, can cause deletions, insertions, and excisions of stretches of DNA, caused by defective DNA repair. Recently, it was reported that CRISPR/Cas9 can be used to eliminate JCV from latently infected cells and prevent new JCV infection (Wollebo, et al., 2015). Recently, the range of targets has been expanded by the introduction of a CRISPR system that utilizes an alternative endonuclease, Cpfl, which is directed by gRNAs different from those which direct Cas9, to target sequences different from those cleaved by Cas9 (Zetsche, et al., 2015). There is a need for compositions and methods for the employment of these gene editing systems in treatments to eliminate latent JCV from patient cells prior to immunosuppressive treatments.

SUMMARY

[00010] The present invention provides a method of eliminating the risk of JCV activation in a subject undergoing immunosuppressive therapy, by administering an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV activation, and treating the subject with an immunosuppressive therapy before, during or after administering the gene editing composition.

[00011] The present invention also provides for a pharmaceutical composition including at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA, the isolated nucleic acid sequences being included in at least one expression vector.

[00012] The present invention further provides for a pharmaceutical composition including at least one isolated nucleic acid sequence encoding at least one TALEN, which targets at least one nucleotide sequence of the JCV genome, the isolated nucleic acid sequence being included in at least one expression vector.

[00013] The present invention still further provides for a pharmaceutical composition including at least one isolated nucleic acid sequence encoding at least one ZFN, which targets at least one nucleotide sequence of the JCV genome, the isolated nucleic acid sequence being included in at least one expression vector.

[00014] The present invention also provides for a pharmaceutical composition for use in eliminating John Cunningham Virus (JCV) from a host cell infected with JCV, including at least one isolated nucleic acid sequence encoding at least one argonaute protein, which targets at least one nucleotide sequence of the JCV genome, the isolated nucleic acid sequences being included in at least one expression vector.

BRIEF DESCRIPTION OF THE DRAWINGS

[00015] Other advantages of the present invention are readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawing wherein:

[00016] FIGURE 1 shows a nucleotide sequence encoding the large T antigen of JCV.

DETAILED DESCRIPTION

[00017] The present invention represents the first application of gene editing technology to the problem of latent JCV reservoirs in candidate patients for immunosuppressive therapy. With the reservoirs eliminated by a gene editing system, the risk of PML by JCV activation is obviated. I mmunosuppressive treatments previously deemed to be too risky for use in the face of latent JCV can now be freely administered, with no need for deliberate under-treatment to reduce risk. The methods and compositions of the present invention can serve as co-therapeutics for any of the treatments listed in TABLE 1, and for all immunosuppressive treatments that can activate JCV, including currently extant treatments, and those to be developed in the future. [00018] CRISPR compositions and methods for eliminating the risk of JCV activation during immunosuppressive therapy.

[00019] One preferred gene editing means for eliminating latent JCV is RNA-guided CRISPR technology. In a CRISPR system, CRISPR clusters encode spacers, which are sequences complementary to target sequences ("protospacers") in a viral nucleic acid, or in another nucleic acid to be targeted. CRISPR clusters are transcribed and processed into mature CRISPR RNAs (crRNAs). CRISPR clusters also encode CRISPR associated (Cas) proteins, which include DNA endonucleases. The crRNA binds to target DNA sequence, whereupon the Cas endonuclease cleaves the target DNA at or adjacent to the target sequence.

[00020] One useful CRISPR system includes the CRISPR associated endonuclease Cas9. Cas9 is guided by a mature crRNA that contains about 20-30 base pairs (bp) of spacer and a trans-activated small RNA (tracrRNA) that serves as a guide for ribonuclease Ill-aided processing of pre-crRNA. The crRNA:tracrRNA duplex directs Cas9 to target DNA via complementary base pairing between the spacer on the crRNA and the target sequence on the target DNA. Cas9 recognizes a trinucleotide (NGG) photospacer adjacent motif (PAM) to decide the cut site (the 3 ^rd nucleotide from PAM). The crRNA and tracrRNA can be expressed separately or engineered into an artificial chimeric small guide RNA (sgRNA) via a synthetic stem loop (AGAAAU) to mimic the natural crRNA/tracrRNA duplex. Such sgRNAs, can be synthesized or in vitro transcribed for direct RNA transfection, or they can be expressed in situ, e.g. from

U6 or Hl-promoted RNA expression vectors. The term "guide RNA" (gRNA) will be used to denote either a crRNA:tracrRNA duplex or an sgRNA. It will be understood the term "gRNA complementary to" a target sequence indicates a gRNA whose spacer sequence is complementary to the target sequence.

[00021] Other CRISPR systems that can be used include CRISPR/Cpfl, which is a DNA-editing technology analogous to the CRISPR/Cas9 system, characterized in 2015 by Feng Zhang's group from the

Broad Institute and MIT. Cpfl is an RNA-guided endonuclease of a class II CRISPR/Cas system. This acquired immune mechanism is found in Prevotella and Francisella bacteria. It prevents genetic damage from viruses. Cpfl genes are associated with the CRISPR locus, coding for an endonuclease that use a guide RNA to find and cleave viral DNA. Cpfl is a smaller and simpler endonuclease than Cas9, overcoming some of the CRISPR/Cas9 system limitations. Cpfl is further described below.

[00022] Argonaute proteins can also be used. Argonaute proteins are proteins of the PIWI protein superfamily that contain a PIWI (P element-induced wimpy testis) domain, a MID (middle) domain, a PAZ (Piwi-Argonaute-Zwille) domain and an N-terminal domain. Argonaute proteins are capable of binding small RNAs, such as microRNAs, small interfering RNAs (siRNAs), and Piwi-interacting RNAs. Argonaute proteins can be guided to target sequences with these RNAs in order to cleave mRNA, inhibit translation, or induce mRNA degradation in the target sequence. There are several different human Argonaute proteins, including AGOl, AG02, AG03, and AG04 that associate with small RNAs. AG02 has slicer ability, i.e. acts as an endonuclease. Argonaute proteins can be used for gene editing. Endonucleases from the Argonaute protein family (from Natronobacterium gregoryi Argonaute) also use oligonucleotides as guides to degrade invasive genomes. Work by Gao et al has shown that the Natronobacterium gregoryi Argonaute (NgAgo) is a DNA-guided endonuclease suitable for genome editing in human cells. NgAgo binds 5' phosphorylatedsingle-stranded guide DNA (gDNA) of ~24 nucleotides, efficiently creates site-specific DNA double-strand breaks when loaded with the gDNA. The NgAgo-gDNA system does not require a protospacer-adjacent motif (PAM), as does Cas9, and preliminary characterization suggests a low tolerance to guide-target mismatches and high efficiency in editing (G+C)-rich genomic targets. The Argonaute protein endonucleases used in the present invention can also be Rhodobacter sphaeroides Argonaute (RsArgo). RsArgo can provide stable interaction with target DNA strands and guide RNA, as it is able to maintain base-pairing in the 3'-region of the guide RNA between the N-terminal and PIWI domains. RsArgo is also able to specifically recognize the 5' base- U of guide RNA, and the duplex-recognition loop of the PAZ domain with guide RNA can be important in DNA silencing activity. Other prokaryotic Argonaute proteins (pAgos) can also be used in DNA interference and cleavage. The Argonaute proteins can be derived from Arabidopsis thaliana, D. melanogaster, Aquifex aeolicus, Thermus thermophiles, Pyrococcus furiosus, Thermus thermophilus JL- 18, Thermus thermophilus strain HB27, Aquifex aeolicus strain VF5, Archaeoglobus fulgidus, Anoxybacillus flavithermus, Halogeometricum borinquense, Microsystis aeruginosa, Clostridium bartlettii, Halorubrum lacusprofundi, Thermosynechococcus elongatus, and Synechococcus elongatus. Argonaute proteins can also be used that are endo-nucleolytically inactive but post-translational modifications can be made to the conserved catalytic residues in order to activate them as endonucleases. Therefore, the present invention also provides for a pharmaceutical composition including at least one isolated nucleic acid sequence encoding at least one argonaute protein, which targets at least one nucleotide sequence of the JCV genome, the isolated nucleic acid sequences being included in at least one expression vector. [00023] I n one preferred embodiment of the present invention, the CRISPR-associated endonuclease is a Cas9 nuclease. The Cas9 nuclease can be a sequence from Staphylococcus aureus. The Cas9 nuclease can also have a nucleotide sequence identical to the wild type Streptococcus pyogenes sequence. I n some embodiments, the CRISPR-associated endonuclease can be a sequence from other species, for example other Streptococcus species, such as Thermophiles; Psuedomonas aeruginosa, Escherichia coli, or other sequenced bacteria genomes and archaea, or other prokaryotic microogranisms. Alternatively, the wild type Streptococcus pyogenes Cas9 sequence can be modified. Preferably, the nucleic acid sequence is be codon optimized for efficient expression in mammalian cells, i.e., "humanized." A humanized Cas9 nuclease sequence can be for example, the Cas9 nuclease sequence encoded by any of the expression vectors listed in Genbank accession numbers KM099231.1 Gl :669193757; KM099232.1 Gl :669193761; or KM099233.1 Gl :669193765. Alternatively, the Cas9 nuclease sequence can be for example, the sequence contained within a commercially available vector such as PX330 or PX260 from Addgene (Cambridge, MA). I n some embodiments, the Cas9 endonuclease can have an amino acid sequence that is a variant or a fragment of any of the Cas9 endonuclease sequences of Genbank accession numbers KM099231.1 Gl :669193757; KM099232.1 Gl :669193761; or KM099233.1 Gl :669193765 or Cas9 amino acid sequence of PX330 or PX260 (Addgene, Cambridge, MA).

[00024] The Cas9 nucleotide sequence can be modified to encode biologically active variants of Cas9, and these variants can have or can include, for example, an amino acid sequence that differs from a wild type Cas9 by virtue of containing one or more mutations (e.g., an addition, deletion, or substitution mutation or a combination of such mutations). One or more of the substitution mutations can be a substitution (e.g., a conservative amino acid substitution). For example, a biologically active variant of a Cas9 polypeptide can have an amino acid sequence with at least or about 50% sequence identity (e.g., at least or about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, or 99% sequence identity) to a wild type Cas9 polypeptide. Conservative amino acid substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine and threonine; lysine, histidine and arginine; and phenylalanine and tyrosine.

[00025] The amino acid residues in the Cas9 amino acid sequence can be non-naturally occurring amino acid residues. Naturally occurring amino acid residues include those naturally encoded by the genetic code as well as non-standard amino acids (e.g., amino acids having the D-configuration instead of the L-configuration). The present peptides can also include amino acid residues that are modified versions of standard residues (e.g. pyrrolysine can be used in place of lysine and selenocysteine can be used in place of cysteine). Non-naturally occurring amino acid residues are those that have not been found in nature, but that conform to the basic formula of an amino acid and can be incorporated into a peptide. These include D-alloisoleucine(2R,3S)-2amino-3-methylpentanoic acid and L-cyclopentyl glycine (S)-2-amino-2-cyclopentyl acetic acid. For other examples, one can consult textbooks or the worldwide web (a site is currently maintained by the California Institute of Technology and displays structures of non-natural amino acids that have been successfully incorporated into functional proteins).

[00026] The Cas9 nuclease sequence can be a mutated sequence. For example the Cas9 nuclease can be mutated in the conserved HNH and RuvC domains, which are involved in strand specific cleavage. For example, an aspartate-to-alanine (D10A) mutation in the RuvC catalytic domain allows the Cas9 nickase mutant (Cas9n) to nick rather than cleave DNA to yield single-stranded breaks, and the subsequent preferential repair through HDR22 can potentially decrease the frequency of unwanted InDel mutations from off-target double-stranded breaks.

[00027] In addition to the wild type and variant Cas9 endonucleases previously described, the present invention also encompasses CRISPR systems including "enhanced-specificity" S. pyogenes Cas9 variants (eSpCas9), which dramatically reduce off-target cleavage. These variants are engineered with alanine substitutions to neutralize positively charged sites in a groove that interacts with the non-target strand of DNA. This modification reduces interaction of Cas9 with the non-target strand, thereby encouraging re-hybridization between target and non-target strands. The effect of this modification is a requirement for more stringent Watson-Crick pairing between the gRNA and the target DNA strand, which limits off-target cleavage (Slaymaker, et al., 2015).

[00028] Especially preferred are three variants found to have the best cleavage efficiency and fewest off-target effects: SpCas9(K855a), SpCas9(K810A/K1003A/rl060A) (a.k.a. eSpCas9 1.0), and SpCas9(K848A/K1003A/R1060A) (a.k.a. eSPCas9 1.1). Techniques for cloning and inducing cellular expression of these enhanced-specificity variants can be found in Slaymaker, et al. (2015), which is incorporated herein in its entirety. The invention is by no means limited to these variants, and also encompasses all Cas9 variants disclosed by Slaymaker, et al. (2015).

[00029] In some embodiments, compositions of the invention can include a CRISPR-associated endonuclease polypeptide encoded by any of the nucleic acid sequences described above. Polypeptides can be generated by a variety of methods including, for example, recombinant techniques or chemical synthesis. Once generated, polypeptides can be isolated and purified to any desired extent by means well known in the art. For example, one can use lyophilization following, for example, reversed phase (preferably) or normal phase HPLC, or size exclusion or partition chromatography on polysaccharide gel media such as Sephadex G-25. The composition of the final polypeptide may be confirmed by amino acid analysis after degradation of the peptide by standard means, by amino acid sequencing, or by FAB- MS techniques.

[00030] In exemplary embodiments, the present invention includes an engineered CRISPR system including Cas9 and one or more gRNAs complementary to a JCV T-Ag sequence. An exemplary JCV genome sequence is the Mad-1 strain, NCBI reference sequence, GenBank number: NC_001699.1, public Gl (Frisque et al, 1984). In the Mad 1 strain, the T-Ag coding region begins at nucleotide (nt) 5013 of the 5130 nt circular Mad-1 JCV genome. The nucleotide sequence of the T-Ag coding region is shown as SEQ ID NO: 13 in FIGURE 1.

[00031] The present invention includes a method of eliminating a risk of JC virus activation in a patient during immunosuppressive therapy including the steps of: administering, to a patient latently or actively infected with JCV, an effective amount of a gene editing composition directed toward at least one target sequence in the JCV genome, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV virus activation, and administering an immunosuppressive therapy to the patient at a time chosen from before, during, and after administration of the gene editing composition. It should be understood that immunosuppressive therapy can be administered at different time points. PML may not occur until the patient is on immunotherapy, at which time the gene editing composition can be used while the patient remains on or is temporarily taken off of the immunosuppressive therapy. The gene editing composition can be any of those described above.

[00032] In a preferred embodiment, the method includes the steps of administering an effective amount of a pharmaceutical composition including an isolated nucleic acid encoding a CRISPR-associated endonuclease, and at least one isolated nucleic acid encoding at least gRNA including a spacer sequence complementary to a target sequence in a JCV DNA, expressing the CRISPR-associated endonuclease and the at least one gRNA in the cells of the patient, cleaving the target sequence in the JCV genome, disrupting the JCV genome, eliminating the JCV infection, eliminating the risk of JCV virus activation, and administering an immunosuppressive therapy to the patient at a time chosen from before, during, and after administration of the CRISPR-associated endonuclease. The CRISPR-associated endonuclease can be any of those described above.

[00033] Wollebo, et al. have disclosed a CRISPR/Cas9 system that can inhibit JCV replication and T-Ag expression in host cells, and to damage the integrity of the JCV genome. These effects caused the excision of both free episomal virus, and virus integrated into host genomes. Harmful off-target effects on healthy genes were not produced (Wollebo, et al., 2015, which is incorporated in its entirety). The Cas9 and gRNA compositions disclosed by Wollebo, et al. (2015), are employed in one embodiment of the method of the present invention.

[00034] A hypothetical exemplary treatment method is disclosed herein, in prophetic Example 1. This example includes the immunosuppressive multiple sclerosis drug natulizumab (Tysabri ^® ), which carries 1/1000 to 13/1000 risk of inducing PML in patients seropositive for PML (Tysabri ^® Prescribing Information, Biogen Idee Inc., Cambridge, MA). The exemplary method is readily modified modifications for use with any immunosuppressive drug regimen, including, but not limited to, the drugs listed in Table 1.

[00035] The gRNAs in Example 1 are those disclosed by Wollebo, et al. (2015), but it will be understood that the present invention is not limited to those gRNAs. The gRNAs include gRNA spacer sequences complementary to the TMl, TM2 or TM3 regions JCV T-antigen sequence. Target sequences can extend from approximately 20 to 40 or more nts in length. It will be understood that, in different strains of JCV, or in mutational variants, sequences homologous to TMl, TM2, and TM3 can be readily identified by well known sequencing and genomics techniques.

[00036] An exemplary target sequence in TMl includes SEQ ID NO: 1, or its complement on the antiparallel strand, SEQ ID NO: 2. The PAM sequence in each strand (shown in lower case bold in

FIGURE 1, and below) can be included in the target sequence, so that the target sequences can include

SEQ ID NO: 3 or its complement on the antiparallel strand, SEQ ID NO: 4. A gRNA complementary to

TMl, designated gRNA ml, can therefore include a spacer sequence complementary to SEQ ID NO: 1,

SEQ ID NO: 2, SEQ ID NO: 3; or SEQ ID NO: 4.

[00037] The nucleotide sequences are as follows:

[00038] AAATGCAAAGAACTCCACCCTGATGAAGGTG (SEQ ID NO: 1)

[00039] A A ATG C A A AG A ACTCC ACCCTG ATG A AG GTG ggg (SEQ ID NO: 2) [00040] C ACCTTT ATC AG G GTG G AGTTCTTTG C ATTT (SEQ ID NO: 3)

[00041] cccCACCTTTATCAGGGTGGAGTTCTTTGCATTT (SEQ ID NO: 4)

[00042] An exemplary target sequence in TM2 includes SEQ ID NO: 5, or its complement on the antiparallel strand, SEQ ID NO: 6. The PAM sequence in each strand can also be included in the target sequence, so that the target sequences can include SEQ ID NO: 7 or its complement on the antiparallel strand, SEQ ID NO: 8. A gRNA complementary to TM2, designated gRNA m2, can therefore include a spacer sequence complementary to SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7; or SEQ ID NO: 8.

[00043] The nucleotide sequences are as follows:

[00044] G ATG A ATG G G A ATCCTG GTG G A ATAC ATTTA ATG AG A AGT (SEQ ID NO: 5)

[00045] G ATG A ATG G G A ATCCTG GTG G A ATAC ATTTA ATG AG A AGTggg (SEQ ID NO: 6)

[00046] ACTTCTCATTAAATGTATTCCACCAGGATTCCCATTCATC (SEQ ID NO: 7)

[00047] cccACTTCTCATTAAATGTATTCCACCAGGATTCCCATTCATC (SEQ ID NO: 8)

[00048] An exemplary target sequence in TM3 includes SEQ ID NO: 9, or its complement on the antiparallel strand, SEQ ID NO: 10. The PAM sequence in each strand can also be included, so that the target sequences can include SEQ ID NO: 11, or its complement, SEQ ID NO: 12. A gRNA complementary to TM3, designated m3, can therefore include a spacer sequence complementary to SEQ ID NO: 9, SEQ

ID NO: 10. SEQ ID NO: 11, or SEQ ID NO: 12.

[00049] THE nucleotide sequences are as follows:

[00050] A AG GT ACTG G CT ATTC A AG G G G CC A ATAG AC AG (SEQ ID NO: 9)

[00051] A AG GT ACTG G CT ATTC A AG G G G CCA ATAG AC AG tgg (SEQ ID NO: 10)

[00052] CTGTCTATTGGCCCCTTGAATAGCCAGTACCTT(SEQ IN NO: 11 )

[00053] ccaCTGTCTATTGGCCCCTTGAATAGCCAGTACCTT (SEQ ID NO: 12)

[00054] It will be understood that the gRNAs of the present invention can also include additional 5' and/or 3' sequences that may or may not be complementary to a target sequence. The spacers of each gRNA can have less than 100% complementarity to its target sequence, for example 95% complementarity. It will also be understood that gRNAs other than those complementary to JCV large T- Ag coding regions are also within the scope of the present invention. This includes gRNAs complementary to target sequences within the regions encoding VP1, VP2, and VP3 and agnoprotein. Also within the scope of the invention are any existing additional sequences adjacent to different PAMs. [00055] The gRNAs can be configured as a single sequence or as a combination of one or more different sequences, e.g., a multiplex configuration. Multiplex configurations can include combinations of two, three, or more different gRNAs. When the compositions are administered in an expression vector, the guide RNAs can be encoded by a single vector. Alternatively, multiple vectors can be engineered to each include two or more different guide RNAs. Especially useful care combinations of gRNAs that cause the excision of viral sequences between cleavage sites, resulting in the ablation of the JCV genome or JCV protein expression. The excised region can vary in size from a single nucleotide to several hundred nucleotides.

[00056] The RNA molecules (e.g., crRNA, tracrRNA, gRNA) may be engineered to comprise one or more modified nucleobases. For example, known modifications of RNA molecules can be found, for example, in Genes VI, Chapter 9 ("Interpreting the Genetic Code"), Lewin, ed. (1997, Oxford University

Press, New York), and Modification and Editing of RNA, Grosjean and Benne, eds. (1998, ASM Press,

Washington DC). Modified RNA components include the following: 2'-0-methylcytidine; N ⁴ - methylcytidine; N ⁴ -2'-0-dimethylcytidine; N ⁴ -acetylcytidine; 5-methylcytidine; 5,2'-0-dimethylcytidine;

5-hydroxymethylcytidine; 5-formylcytidine; 2'-0-methyl-5-formaylcytidine; 3-methylcytidine; 2- thiocytidine; lysidine; 2'-0-methyluridine; 2thiouridine; 2-thio-2'-0-methyluridine; 3,2'-0- dimethyluridine; 3-(3-amino-carboxypropyl)uridine; 4-thiouridine; ribosylthymine; 5,2'-0- dimethyluridine; 5-methyl-2thiouridine; 5-hydroxyuridine; 5-methoxyuridine; uridine 5-oxyacetic acid; uridine 5-oxyacetic acid methyl ester; 5-carboxymethyluridine; 5-methoxycarbonylmethyluridine;

5methoxycarbonylmethyl-2'-0-methyluridine; 5-methoxycarbonylmethyl-2'-thiouridine; 5- carbamoylmethyluridine; 5-carbamoylmethyl-2'-0-methyluridine; 5-(carboxyhydroxymethyl) uridine; 5-

(carboxyhydroxymethyl) uridinemethyl ester; 5-aminomethyl-2-thiouridine;

5methylaminomethyluridine; 5-methylaminomethyl-2-thiouridine; 5-methylaminomethyl-

2selenouridine; 5-carboxymethylaminomethyluridine; 5-carboxymethylaminomethyl-2'-Omethyl- uridine; 5-carboxymethylaminomethyl-2-thiouridine; dihydrouridine; dihydroribosylthymine; 2'- methyladenosine; 2-methyladenosine; N ⁶ -methyladenosine; N ⁶ , N ⁶ -dimethyladenosine; N ⁶ ,2'-0- trimethyladenosine; 2-methylthio-N ⁶ N-isopentenyladenosine; N ⁶ -(cis-hydroxyisopentenyl)-adenosine;

2-methylthio-N ⁶ -(cis-hydroxyisopentenyl)-adenosine; N ⁶ -glycinylcarbamoyl)adenosine; N ⁶ - threonylcarbamoyl adenosine; N ⁶ -methyl-N ⁶ threonylcarbamoyl adenosine; 2-methylthio-N ⁶ -methyl-N ⁶ - threonylcarbamoyl adenosine; N ⁶ hydroxynorvalylcarbamoyl adenosine; 2-methylthio-N ⁶ - hydroxnorvalylcarbamoyl adenosine; 2-O-ribosyladenosine (phosphate); inosine; 2'0-methyl inosine; 1- methyl inosine; l;2'-0-dimethyl inosine; 2'-0-methyl guanosine; 1-methyl guanosine; N ² -methyl guanosine; N2,N2-dimethyl guanosine; N2, 2'-0-dimethyl guanosine; N ² , N ² , 2'-0-trimethyl guanosine; 2'-0-ribosyl guanosine (phosphate); 7-methyl guanosine; N ² ;7-dimethyl guanosine; N ² ; N ² ;7-trimethyl guanosine; wyosine; methylwyosine; under-modified hydroxywybutosine; wybutosine; 30 hydroxywybutosine; peroxywybutosine; queuosine; epoxyqueuosine; galactosyl-queuosine; mannosyl- queuosine; 7-cyano-7-deazaguanosine; arachaeosine [also called 7-formamido-7 -deazaguanosine]; and 7-aminomethyl-7-deazaguanosine. The methods of the present invention or others in the art can be used to identify additional modified RNA molecules.

[00057] The gRNAs of the present invention are not limited to those complementary to sequences found within the TM1, TM2 or TM3 region of JCV T-antigen. Other regions of JCV can be targeted by CRISPR systems with suitably designed gRNAs. For CRISPR systems employing S. pyogenes Cas9, the PAM sequence can be AGG, TGG, CGG or GGG. Candidate target sequences can be identified by proximity to a 5' PAM such as AGG, TGG, CGG or GGG. Other Cas9 orthologs may have different PAM specificities. For example, Cas9 from S. Thermophiles requires 5'-N NAGAA for CRISPR 1 and 5'-NGGNG for CRISPR3) and Neiseria menigiditis requires 5'-N NNNGATT). The specific sequence of the gRNA may vary, but useful gRNA sequences will be those that minimize off target effects while achieving high efficiency and complete elimination of JCV. Efficiency and off target effects of candidate gRNAs can be determined by the assays disclosed in by Wollebo, et al. (2015).

[00058] The CRISPR/Cas9 compositions are preferably administered as pharmaceutical compositions, which can be prepared in a variety of ways known to one of ordinary skill in the art. Preferably, the CRISPR/Cas9 com positions are encoded in expression vectors, which are formulated in compositions for administration to a patient, or in some cases, for treatment of cultured patient cells for adoptive transfer to the patient. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes. Since latent JCV can dwell in both glial cells of the brain and other CNS tissues, and in a variety of lymphoid and nonlymphoid peripheral tissues, delivery by multiple routes, both local and systemic, may be desirable.

[00059] Administration may be topical (including ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. Methods for ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection or introduction by balloon catheter or ophthalmic inserts surgically placed in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion or catheterization; or intracranial, e.g., intrathecal or intraventricular administration, for example by means of a cannula. Parenteral administration can be in the form of a single bolus dose, or may be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, powders, and the like. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Glial and mesenchymal cells that have been transduced with gene editing components may be used to conduct these components to sites in the CNS (Lee, et al., 2013, San Sebastian, et al., 2013)

[00060] The present invention also includes pharmaceutical compositions which contain, as the active ingredient, nucleic acids, vectors, exosomes, and nanoclews described herein, in combination with one or more pharmaceutically acceptable carriers. We use the terms "pharmaceutically acceptable" (or "pharmacologically acceptable") to refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal or a human, as appropriate. The term "pharmaceutically acceptable carrier," as used herein, includes any and all solvents, dispersion media, coatings, antibacterial, isotonic and absorption delaying agents, buffers, excipients, binders, lubricants, gels, surfactants and the like, that may be used as media for a pharmaceutically acceptable substance. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, tablet, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semisolid, or liquid material (e.g., normal saline), which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), lotions, creams, ointments, gels, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. As is known in the art, the type of diluent can vary depending upon the intended route of administration. The resulting compositions can include additional agents, such as preservatives. In some embodiments, the carrier can be, or can include, a lipid-based or polymer-based colloid. In some embodiments, the carrier material can be a colloid formulated as a liposome, a hydrogel, a microparticle, a nanoparticle, or a block copolymer micelle. As noted, the carrier material can form a capsule, and that material may be a polymer-based colloid. Further description of exemplary pharmaceutically acceptable carriers and diluents, as well as pharmaceutical formulations, can be found in Remington's Pharmaceutical Sciences, a standard text in this field, and in USP/N F. Other substances may be added to the compositions to stabilize and/or preserve the compositions.

[00061] The term "effective amount" of a pharmaceutical com position, as used herein, refers to any amount that induces a desired response while not inducing significant toxicity in the patient. For the present invention, the desired effect of a gene editing composition is the elimination of JCV from host tissues. The amount can be determined by assessing a patient's response after administration of a known amount of a particular composition. I n addition, the level of toxicity, if any, can be determined by assessing a patient's clinical symptoms before a nd after administering a known amount of a particular com position. It is noted that the effective amount of a particular composition administered to a patient can be adjusted according to a desired outcome as well as the patient's response and level of toxicity. Significant toxicity can vary for each particular patient and depends on multiple factors including, without limitation, the patient's disease state, age, and tolerance to side effects.

[00062] The nucleic acid sequences of the invention can be delivered to an appropriate cell of a subject. This can be achieved by, for example, the use of a polymeric, biodegradable microparticle or microcapsule delivery vehicle, sized to optimize phagocytosis by phagocytic cells such as macrophages.

For example, PLGA (poly-lacto-co-glycolide) microparticles approximately 1-10 μιη in diameter can be used. The polynucleotide is encapsulated in these microparticles, which are taken up by macrophages and gradually biodegraded within the cell, thereby releasing the polynucleotide. Once released, the

DNA is expressed within the cell. A second type of microparticle is intended not to be taken up directly by cells, but rather to serve primarily as a slow-release reservoir of nucleic acid that is taken up by cells only upon release from the micro-particle through biodegradation. These polymeric particles should therefore be large enough to preclude phagocytosis (i.e., larger than 5μιη and preferably larger than

20μιη). Another way to achieve uptake of the nucleic acid is using liposomes, prepared by standard methods. The nucleic acids can be incorporated alone into these delivery vehicles or co-incorporated with tissue-specific antibodies, for example antibodies that target cell types that are common latently infected reservoirs of HIV infection, for example, brain macrophages, microglia, astrocytes, and gut- associated lymphoid cells. Alternatively, one can prepare a molecular complex composed of a plasmid or other vector attached to poly-L-lysine by electrostatic or covalent forces. Poly-L-lysine binds to a ligand that can bind to a receptor on target cells. Delivery of "naked DNA" (i.e., without a delivery vehicle) to an intramuscular, intradermal, or subcutaneous site, is another means to achieve in vivo expression. I n the relevant polynucleotides (e.g., expression vectors) the nucleic acid sequence encoding an isolated nucleic acid sequence comprising a sequence encoding a CRISPR-associated endonuclease and a guide RNA is operatively linked to a promoter or enhancer-promoter combination. Promoters and enhancers are described above.

[00063] I n some embodiments, the compositions of the invention can be formulated as a nanoparticle, for example, nanoparticles comprised of a core of high molecular weight linear polyethylenimine (LPEI) complexed with DNA and surrounded by a shell of polyethyleneglycol-modified (PEGylated) low molecular weight LPEI .

[00064] The nucleic acids and vectors may also be applied to a surface of a device (e.g., a catheter) or contained within a pump, patch, or other drug delivery device. The nucleic acids and vectors of the invention can be administered alone, or in a mixture, in the presence of a pharmaceutically acceptable excipient or carrier (e.g., physiological saline). The excipient or carrier is selected on the basis of the mode and route of administration. Suitable pharmaceutical carriers, as well as pharmaceutical necessities for use in pharmaceutical formulations, are described in Remington's Pharmaceutical Sciences (E. W. Martin), a well-known reference text in this field, and in the USP/NF (United States Pharmacopeia and the National Formulary).

[00065] I n some embodiments, the compositions can be formulated as a nanoparticle encapsulating a nucleic acid encoding Cas9 or a variant Cas9, or Cpfl, or a variant of Cpfl, or any other effective g-RNA guided DNA endonuclease; and at least one gRNA sequence complementary to a target

HIV; or it can include a vector encoding these components. Alternatively, the compositions can be formulated as a nanoparticle encapsulating the CRISPR-associated endonuclease the polypeptides encoded by one or more of the nucleic acid compositions of the present invention.

[00066] Preferably, gene editing treatments are administered only to patients determined to be in need of the treatments, that is, patients determined to harbor latent JCV infection. The determination can be made by any effective screening test known in the art. ELISA assays for anti-JCV antibodies, and quantitative PCR for JCV DNA, in blood, serum, CSF, or other body fluids are preferred. An inclusion body diagnostic assay can be alternatively employed. Thus, the method of the present invention can include, prior to the administering step, the step of prior to step of administering, the step of screening a patient for latent or active JCV infection.

[00067] It is also preferable that a patient who is identified as having a latent or active JCV infection be monitored to ensure that the infection is resolved prior to the commencement of immunosuppressive therapy. If immunosuppressive therapy is delivered over a long course, it is also desirable to monitor the patient for the recurrence of JCV infection, for example, by reactivation of small, untreated reservoirs of latent virus. Monitoring can be performed by any suitable method, such as the ELISA and PCR methods previously stated. Thus, the method of the present invention can also include, at any point after the step of disrupting the JCV genome, the step of determining that the JCV infection has been resolved.

[00068] Dosage, toxicity, and therapeutic efficacy the gene editing compositions can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. The Cas9/gRNA compositions that exhibit high therapeutic indices are preferred. While Cas9/gRNA compositions that exhibit off target effects or other toxic side effects may be used, care should be taken to design a delivery system that targets such compositions to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. Restriction of side effects can also be accomplished by including in expression vectors one or more tissue specific promoters. Additionally, in order to enhance the in vivo half-life of the administered compound, the compositions may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compositions. A variety of methods are available for preparing liposomes, as described in, e.g., Szoka, et al., U.S. Pat. Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference. Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with a tissue specific antibody. The liposomes will be targeted to and taken up selectively by the tissue. [00069] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compositions lies generally within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any composition used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays.

[00070] Vectors. The present invention includes a vector comprising one or more cassettes for expression of CRISPR components such as one or more gRNAs and a Cas endonuclease such as Cas9. The vector can be any vector that is known in the art and is suitable for expressing the desired expression cassette. A number of vectors are known to be capable of mediating transfer of gene products to mammalian cells, as is known in the art and described herein. A "vector" (sometimes referred to as gene delivery or gene transfer "vehicle") refers to a macromolecule or complex of molecules comprising a polynucleotide to be delivered to a host cell, either in vitro or in vivo. The polynucleotide to be delivered may comprise a coding sequence of interest in gene therapy.

[00071] A preferred vector is a lentiviral vector. Lentiviral vectors have the advantage of providing efficient transduction of both proliferating and resting cells, stable expression of delivered genes by integration into host chromatin, and the absence of interference from preexisting viral immunity. In experiments disclosed in Wollebo, et al., (2015), drug-inducible lentiviral expression vectors for Cas9/gRNA components were shown to be effective in ablating JCV T-Ag expression in infected cells. In an exemplary configuration, host cells were stably transduced with Cas9 or another suitable CRISPR endonuclease in doxycycline inducible lentiviral vector. When elimination of JCV was desired, the host cells were transduced with one or more gRNAs and treated with doxycycline, to activate expression of Cas9, to cause guided cleavage of the JCV genome and inactivation of virus. Alternatively, one or more gRNAs can be transduced stably, in a drug-inducible manner, or both a CRISPR associated endonuclease and gRNAs can be so transduced. In a clinical situation, this treatment could be used for patients at risk of JCV infection, with the CRISPR components being activated upon evidence of initial or recurrent infection.

[00072] Therefore, the present invention encompasses a vector composition for use in eliminating

JCV from a host cell. The vector composition includes at least one isolated nucleic acid sequence encoding a CRISPR-associated endonuclease, and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA. The isolated nucleic acid sequences are included in at least one expression vector, which induces the expression of the CRISPR-associated endonuclease and the at least one gRNA in a host cell.

[00073] The present invention is by no means limited to the plasmid and lentiviral vectors described in Examples 1-2. Other preferred vectors include adenovirus vectors and adeno-associated virus vectors. These have the advantage of not integrating into host cell DNA. Adenoviruses have the additional advantage of having a large packaging ca pacity (Ding, et al., 2014). Many other recombinant viral vectors are also suitable, including, but not limited to, vesicular stomatitis virus (VSV) vectors, pox virus vectors, and retroviral vectors.

[00074] A "recombinant viral vector" refers to a viral vector comprising one or more heterologous gene products or sequences. Since many viral vectors exhibit size constraints associated with packaging, the heterologous gene products or sequences are typically introduced by replacing one or more portions of the viral genome. Such viruses may become replication defective, requiring the deleted function(s) to be provided in trans during viral replication and encapsidation (by using, e.g., a helper virus or a packaging cell line carrying gene products necessary for replication and/or encapsidation). Modified viral vectors in which a polynucleotide to be delivered is carried on the outside of the viral particle have also been described.

[00075] Retroviral vectors include Moloney murine leukemia viruses and HIV-based viruses. One preferred HIV-based viral vector comprises at least two vectors wherein the gag and pol genes are from an HIV genome and the env gene is from another virus. DNA viral vectors are preferred. These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex I virus (HSV) vector.

[00076] Pox viral vectors introduce the gene into the cells cytoplasm. Avipox virus vectors result in only a short term expression of the nucleic acid. Adenovirus vectors, adeno-associated virus vectors and herpes simplex virus (HSV) vectors may be an indication for some invention embodiments. The adenovirus vector results in a shorter term expression (e.g., less than about a month) than adeno- associated virus, in some embodiments, may exhibit much longer expression. The particular vector chosen will depend upon the target cell and the condition being treated. The selection of appropriate promoters can readily be accomplished. I n some embodiments, a high expression promoter can be used. An example of a suitable promoter is the 763-base-pair cytomegalovirus (CMV) promoter. The Rous sarcoma virus (RSV) and MMT promoters may also be used. Certain proteins can expressed using their native promoter. Other elements that can enhance expression can also be included such as an enhancer or a system that results in high levels of expression such as a tat gene and tar element. This cassette can then be inserted into a vector, e.g., a plasmid vector such as, pUC19, pUC118, pBR322, or other known plasmid vectors, that includes, for example, an E. coli origin of replication. The plasmid vector may also include a selectable marker such as the β-lactamase gene for ampicillin resistance, provided that the marker polypeptide does not adversely affect the metabolism of the organism being treated. The cassette can also be bound to a nucleic acid binding moiety in a synthetic delivery system, such as the system disclosed in WO 95/22618.

[00077] Another delivery method is to use single stranded DNA producing vectors which can produce the expressed products intracellularly. See for example, Chen et a I, BioTechniques, 34: 167-171 (2003), which is incorporated herein, by reference, in its entirety.

[00078] Expression may be controlled by any promoter/enhancer element known in the art that is functional in the host selected for expression. Besides the promoters described in the examples section, other promoters which may be used for gene expression include, but are not limited to, cytomegalovirus (CMV) promoter, the SV40 early promoter region, the promoter contained in the 3' long terminal repeat of Rous sarcoma virus, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene; prokaryotic expression vectors such as the beta-lactamase, or the tac promoter; promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter; and the animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells; insulin gene control region which is active in pancreatic beta cells, immunoglobulin gene control region which is active in lymphoid cells, mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells, albumin gene control region which is active in liver, alpha-fetoprotein gene control region which is active in liver, alpha 1-antitrypsin gene control region which is active in the liver, beta-globin gene control region which is active in myeloid cells, myelin basic protein gene control region which is active in oligodendrocyte cells in the brain, myosin light chain-2 gene control region which is active in skeletal muscle, and gonadotropic releasing hormone gene control region which is active in the hypothalamus. [00079] A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences. Suitable vectors include derivatives of SV40 and known bacterial plasmids, e.g., E. coli plasmids col El, pCRl, pBR322, pMal-C2, pET, pGEX, pMB9 and their derivatives, plasmids such as RP4; phage DNAs, e.g., the numerous derivatives of phage 1, e.g., NM989, and other phage DNA, e.g., M13 and filamentous single stranded phage DNA; yeast plasmids such as the 2μ plasmid or derivatives thereof, vectors useful in eukaryotic cells, such as vectors useful in insect or mammalian cells; vectors derived from combinations of plasmids and phage DNAs, such as plasmids that have been modified to employ phage DNA or other expression control sequences; and the like.

[00080] If desired, the polynucleotides of the invention may also be used with a microdelivery vehicle such as cationic liposomes and other lipid-containing complexes, and other macromolecular complexes capable of mediating delivery of a polynucleotide to a host cell.

[00081] Vectors can also comprise other components or functionalities that further modulate gene delivery and/or gene expression, or that otherwise provide beneficial properties to the targeted cells. Such other components include, for example, components that influence binding or targeting to cells (including components that mediate cell-type or tissue-specific binding); components that influence uptake of the vector nucleic acid by the cell; components that influence localization of the polynucleotide within the cell after uptake (such as agents mediating nuclear localization); and components that influence expression of the polynucleotide. Such components can also include markers, such as detectable and/or selectable markers that can be used to detect or select for cells that have taken up and are expressing the nucleic acid delivered by the vector. Such components can be provided as a natural feature of the vector (such as the use of certain viral vectors which have components or functionalities mediating binding and uptake), or vectors can be modified to provide such functionalities. Other vectors include those described by Chen et ai; BioTechniques, 534: 167-171

(2003). A large variety of such vectors are known in the art and are generally available.

[00082] Delivery of vectors can also be mediated by exosomes. Exosomes are lipid nanovesicles released by many cell types. They mediate intercellular communication by transporting nucleic acids and proteins between cells. Exosomes contain RNAs, miRNAs, and proteins derived from the endocytic pathway. They may be taken up by target cells by endocytosis, fusion, or both. Typically, the receipt of endosomal contents alters the functions of the receiving cells (Lee, et al., 2012).

[00083] Exosomes can be harnessed to deliver nucleic acids to target cells. In a preferred method, exosomes are produced in vitro by producer cells, purified, and loaded with a nucleic acid cargo by electroporation, or by lipid transfection agents (Marcus and Leonard, 2013, Shtam, et al., 2013). The cargo can include expression constructs for a Cas endonuclease and one or more gRNAs. Suitable techniques can be found in Kooijmans, et al. (2012), Lee, et al. (2012), Marcus and Leonard (2013), Shtam, et al. (2013), or references therein. An exemplary kit for producing and loading exosomes is the ExoFect™ kit (System Biosciences, Inc., Mountain View, CA).

[00084] Exosomes can also be targeted for preferential uptake by particular cell types. A targeting strategy especially useful for the present invention is disclosed by Alvarez-Ervitti, et al. (2011). Using techniques disclosed therein, exosomes can be decorated with rabies viral glycoprotein (RVG) peptide. Exosomes bearing RVG home specifically to the brain, especially to neurons, oligodendrocytes, and microglia, with little nonspecific accumulation in other tissues.

[00085] The expression constructs of the present invention can also be delivered by means of nanoclews. Nanoclews are a cocoon-like DNA nanocomposites (Sun, et al., 2014). They can be loaded with nucleic acids for uptake by target cells and release in target cell cytoplasm. Methods for constructing nanoclews, loading them, and designing release molecules can be found in Sun, et al. (2014) and Sun, et al. (2015).

[00086] The gene editing constructs of the present invention can also be delivered not by induced expression by host cells, but by direct delivery, that is, delivery of a Cas nuclease protein, such as Cas9 protein, plus one of more gRNAs. Exosomes are a preferred vehicle for direct delivery, as they can be loaded with both proteins and RNAs (Alvarez-Ervitti, et al., 2011; Marcus and Leonard, 2013). An exemplary method of protein loading into exosomes is by the expression of a protein as a fusion with endosomal proteins such as lactadherin, in exosome producing cells. Another favorable feature of exosomes is their targetability to specific sites, such as the brain, as previously described. gRNAs can be loaded into the same exosomes as Cas nuclease protein, preferably, in the form of Cas/gRNA complexes. Cas endonucleases and gRNAs can alternatively be loaded into separate exosomes, for simultaneous or staged delivery.

[00087] Direct delivery of gene editing complexes can also be accomplished by menas of nanoclews. Sun, et al. (2015) disclose techniques for loading Cas9/gRNA complexes into nanoclews for uptake and release into receiving cells.

[00088] Direct delivery vehicles can be administered by any appropriate route, including, but not limited to, i.v., i.p, rectal, intrathecal, intracranial, inhalation, and per os, including in pill form.

[00089] The present invention is not limited to CRISPR systems that include Cas9 endonucleases. It also encompasses compositions and methods entailing the use of any CRISPR associated endonuclease that is capable of cleaving a viral genome after guidance to a PAM site by a gRNA. Examples include endonucleases of the family Cpfl (CRISPR from Prevotella and Francisella 1) (Zetsche, et ai, 2015). Two Cpfl endonucleases have so far been shown to be effective at editing genes in a cultured human kidney cell system: Acidaminococcus sp. BV3L6 Cpfl, and Lachnospiraceae bacterium ND2006 Cpfl.

[00090] Cpfl endonucleases expand the range of possible targets in JCV and other polyoma viruses, because they recognize a PAM different from the cytosine rich PAM recognized by Cas9. Cpfl recognizes a thymine rich PAM, with a consensus sequence TTN, and that PAM is located at the 5' end of the target sequence. Cpfl is guided by a smaller, simpler gRNA than that of Cas9 systems. Instead of a two-unit gRNA including crRNA and tracrRNA, or an engineered chimeric hybrid of crRNA and tracrRNA, Cpfl is guided by single guide RNA, termed gRNA. The Cpfl molecule is also smaller than the Cas9 molecule. This greater simplicity and smaller size facilitates both the design and use of CRISPR/Cpfl systems, and the delivery of the endonuclease component to the nucleus of a host cell.

[00091] Hypothetical target sequences for Cpfl, based on 3' adjacency to 5'TTN sequences in the JCV T-Ag genome, are disclosed as a prophetic example, Example 2. A hypothetical method of eliminating the risk of JCV activation during an immunosuppressive therapy regime is also disclosed in Example 2. Therefore, the present invention encompasses a method for eliminating a risk of JCV activation in a subject during immunosuppressive therapy including the steps of: administering, to a subject infected with JCV, an effective amount of a gene editing composition including at least one isolated nucleic acid sequence encoding Cpfl and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA; cleaving the target sequence in the JCV genome; disrupting the JCV genome; eliminating the JCV infection; eliminating the risk of JCV virus activation; and administering an immunosuppressive therapy to the subject.

[00092] The gRNAs of the present invention are synthesized generally as described by Zetsche, et al. Cloning of the gRNAs into vectors for expression in host cells is as described in Hu, et ai, 2014, and in

WO2015/031775 to Khalili, et ai, both of which are incorporated in their entirety. Screening of Cpfl/gRNA combinations for gene editing activity is performed by genomic analyses, Surveyor assays, and assays of viral infection, activation, and expression, as disclosed in Hu, et al., 2014, and in WO2015/031775 to Khalili, et al. Detailed techniques for the use of Cpfl/gRNA combinations, included suggested vectors, are as described previously for Cas9/gRNA combinations.

[00093] The present invention is not limited to CRISPR systems including Cas9 or Cpfl nucleases, or the gRNAs previously disclosed. The present invention encompasses all methods for JCV elimination by any gRNA guided nuclease, both extant and to be discovered in the future, that can eradicate or disrupt the JCV replication cycle and subsequent destruction of nerve cells by PML.

[00094] ZFN and TALEN compositions and methods for eliminating risk of JCV activation during immunosuppressive therapy.

[00095] The present invention includes compositions of engineered restriction enzymes of the ZFN (zinc finger nuclease) and TALEN (transcription activator-like effector nuclease) families. Unlike the CRISPR systems, these nucleases are not guided to target sites by gRNAs, but are engineered to recognize specific target sequences, to which they bind and then cleave. When cleavage is followed by nonhomologous end joining, random insertions or deletions occur at the cleavage site, usually causing a functional knock-out of the affected gene.

[00096] ZFNs are hybrid proteins, which combine a zinc finger DNA binding domain, with a DNA cleaving domain, derived from the nuclease domain of the restriction endonuclease Fokl. To produce double stranded breaks, a pair of ZFNs are administered, each recognizing a different 12-18 base target sequence, with the target sequences being separated by 4-7 base pairs, to allow formation of an active Fokl dimer. ZFNs are typically encoded into plasmids, viruses, or other vectors for expression in target cells (Urnov, et al., 2010). ZFNs specific for target sequences in the JCV genome can be designed by using publically available programs, such as ZiFiT (Sander, et al., 2010).

[00097] TALENs are proteins which contain DNA-binding domains composed of a series of 33-35- amino-acid repeat domains that each recognize a single base pair. Modular TALEN repeats can be linked together to recognize contiguous DNA sequences. TALEN repeats can be combined to recognize and cleave virtually any desired DNA sequence. (Miller, et al., 2011). TALENS specific for target sequences in the JCV genome can be designed by using publically available design programs, such as the TALE-NT 2.0 web interface, freely available online (Doyle, et al., 2012).

[00098] The present invention includes all ZFN and TALEN molecules, and their variants, extant or developed in the future, which are useful to cleave the JCV genome to disrupt the viral replication cycle and eradicate the virus.

[00099] EXAMPLE 1: CRISPR/Cas9 compositions and methods for the elimination of JCV, as a co-therapeutic treatment with natalizumab.

[000100] Natalizumab (Tysabri ^® ) is a humanized monoclonal antibody against the cell adhesion molecule a4-integrin. In a co-therapeutic treatment regime, a subject found to harbor a latent JCV infection is treated with a CRISPR/Cas9 pharmaceutical composition until the infection is eliminated. The patient is then treated with natalizumab, as a remedy for multiple sclerosis or another autoimmune disease.

[000101] A subject can be screened for the presence of JCV infection by ELISA for anti-JCV antibodies in blood or serum. An exemplary ELISA is STRATI FY -JCV ^® , available from Biogen, Cambridge, MA. Screening can alternatively be by quantitative PCR analysis for JCV DNA in a body fluid such as cerebrospinal fluid, blood, or urine. A suitable PCR test is available from Viracor-IBT Laboratories (Lee's Summit, MO).

[000102] If the subject is found to be infected with JCV, a course of co-therapeutic treatment is begun, with the administration of a pharmaceutical composition including at least one isolated nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease, and at least one gRNA having a spacer sequence complementary to a target sequence in a JCV DNA. The preferred target sequences include any combination of ml, m2, and m3, as previously described.

[000103] The treatment continues until all evidence of JCV infection is eliminated, as determined by, for example, ELISA or quantitative PCR. At that point, natalizumab therapy is begun. A typical course of natalizumab includes a 300 mg intravenous infusion of a 2.6 mg/mL solution over one hour every four weeks (Tysabri ^® Prescribing Information). It is preferred that screening for JCV be repeated at suitable intervals over the course of natalizumab treatment, so that any reactivation of new or hidden virus reservoirs can be reacted to before symptoms of PML occur.

[000104] It is possible that a subject with active JCV infection and symptomatic PML could be considered for treatment with natalizumab. In this case, the screening test establishes a baseline of JCV presence. The method is otherwise performed as previously described, with natalizumab treatment commencing upon both resolution of the symptoms and elimination of residual JCV. [000105] EXAMPLE 2: CRISPR/Cpfl compositions and methods for the elimination of JCV, as a co-therapeutic treatment with natalizumab.

[000106] Hypothetical target sequences for Cpfl, based on 3' adjacency to 5'TTN sequences in the JCV T-Ag genome, are disclosed in TABLE 2, as target sequences cml-cm236. Gene editing compositions of the present invention include at least one gRNA complementary to one of the listed target sequences. A gRNA of the present invention may or may not include a sequence complementary to the PAM sequence of a target sequence, which is listed in parentheses at the 5' end of each target sequence in TABLE 2. A gRNA may be complementary to a truncated variation of a listed sequence, for example one that is truncated by 1, 2, 3, or more nucleotides on the 3' end. A gRNA may be less than 100% complementary a target sequences listed in TABLE 2. For example, a gRNA can be 95% complimentary to a listed target sequence. The gRNA sequence can include additional 5' and/or 3' sequences that may not be complementary to a target sequence. The present invention includes gRNAs that are complementary to the antisense strand of each of the listed target sequences (not shown), or 95% complementary, or complementary to an antisense sequence that is truncated by 1, 2, 3, or more nucleotides. The gRNA sequences can be employed in a multiplex configuration, including combinations of two, three, four, five, six, seven, eight, nine, ten, or more different gRNAs.

[000107] It will be understood that Table 2 includes only a representative sample of target sequences in the JCV T-Ag genome. Additional sequences in other regions of the JCV genome are also within the scope of this invention, such as the regions encoding VP1, VP2, and VP3 and agnoprotein. Also within the scope of the invention are any existing additional sequences adjacent to different PAMs.

[000108] Prior to the start of natalizumab therapy, an effective dose of a composition including one or any combination of gRNAs complimentary to the sequences listed in TABLE 2, and Cpfl, are administered to a subject in need of elimination of latent JCV. Preferably, the gRNAs and Cpfl are encoded in one or more expression vectors, in a suitable pharmaceutical composition, as described in prophetic Example 1. The protocol for natalizumab treatment is also as described in Example 1. TABLE 2. Cpfl/gRNA TARGET SEQUENCES

IN THE JCV GENOME. cml: (TTA)CTTAACAGTTGCAGTTATTTTGGG (SEQ ID NO: 14)

cm2: (TTA )TTTTG G G G G AG G G GTCTTTG GTTT (SEQ ID NO: 15)

cm3: (TTA)GCTTTCATAGTAGAAAATGTATAC (SEQ ID NO: 16)

cm4: (TTA)TTTCTAAATCCAGCCTTTCTTTCC (SEQ ID NO: 17)

cm5: (TTA )GTG ATTTTCTC AG GT AG G CCTTTG (SEQ ID NO: 18)

cm6: (TTA)CAATTCCAGGTGGAAACACCTGTG (SEQ ID NO: 19)

cm7: (TTA)ACTTTTACACTTCCATCTAAGTAA (SEQ ID NO: 20)

cm8: (TTA)CACTTCCATCTAAGTAATCTCTTA (SEQ ID NO: 21)

cm9: (TTA ) AG C A ATC A AG GTTG CTTATG CC AT (SEQ ID NO: 22)

cmlO: (TTA)TG CC ATG CCCTG AAG GTAAATCCC (SEQ ID NO: 23)

cm 11: (TTA)CATCCTCAAATACAACCATAAACT (SEQ ID NO: 24)

cml2: (TTA)ATCTTTCTAATGGCATATTAACAT (SEQ ID NO: 25)

cml3: (TTA)ACATTTAATGACTTTCCCCCACAG (SEQ ID NO: 26)

cml4: (TTA)ATGACTTTCCCCCACAGAGATCAA (SEQ ID NO: 27)

cml5: (TTA)ATACAATGCATTTTAGAAAGTCAT (SEQ ID NO: 28)

cml6: (TTA)AGTCCATTTTATCAAGCAAGAAAT (SEQ ID NO: 29)

cml7: (TTA)TC AAG CAAG AAATTAAACCTTTCA (SEQ ID NO: 30)

cml8: (TTA)AAGTGATTTGGCTGATCCTTTTTT (SEQ ID NO: 31)

cml9: (TTA)AAGTCATGCTCCTTAAGGCCCCCC (SEQ ID NO: 32) cm20: (TTA)TTCACACCTTTACAAATTAAAAAA (SEQ I D NO: 33) cm21: (TTA)CAAATTAAAAAACTAAAGGTACAT (SEQ ID NO: 34) cm22: (TTA) AAAAACTAAAG GTACATAGTTTTT (SEQ I D NO: 35) cm23: (TTA)TTAATTGCTGACACTCTATGTCTA (SEQ I D NO: 36) cm24: (TTA)ATTGCTGACACTCTATGTCTATGT (SEQ I D NO: 37) cm25: (TTA)AGAAAAACAAAATATTATGACCCC (SEQ I D NO: 38) cm26: (TTA)TAAAAGTTACAGAATATTTTTCCA (SEQ I D NO: 39) cm27: (TTA)CAGAATATTTTTCCATAAGTTTCT (SEQ ID NO: 40) cm28: (TTA)GTGGTATACACAGCAAAAGAAGCA (SEQ ID NO: 41) cm29: (TTA)GGTGGGGTAGAGTGTTGGGATCCT (SEQ I D NO: 42) cm30: (TTA)AATGTATTCCACCAGGATTCCCAT (SEQ ID NO: 43) cm31: (TTA)AGTTTATTGTAAAAAACAAAATGC (SEQ I D NO: 44) cm32: (TTA)TTGTAAAAAACAAAATGCCCTGCA (SEQ ID NO: 45) cm33: (TTA)AAGCTTTAGATCCCTGTAGGGGGT (SEQ I D NO: 46) cm34: (TTA)AGTCACACCCAAACCATTGTCTGA (SEQ I D NO: 47) cm35: (TTA)AAAATTTTCTGTTTCTATGCCTTA (SEQ ID NO: 48) cm36: (TTA) G C ATG C AC ATTA A AC AG G G G C A AT (SEQ ID NO: 49) cm37: (TTA)AACAGGGGCAATGCACTGAAGGAT (SEQ I D NO: 50) cm38: (TTA)GTGGCACAGTTAGGCCATTCCTTG (SEQ ID NO: 51) cm39: (TTA) G G CC ATTCCTTG C A ATA A AG G GTA (SEQ ID NO: 52) cm40: (TTA)GGAGGAAAATCACAACCAACCTCT (SEQ ID NO: 53) cm41: (TTA)CACCTTGTTCCATTTTTTTATATA (SEQ ID NO: 54) cm42: (TTA)TATAAAAAATTCATTCTCTTCATC (SEQ I D NO: 55) cm43: (TTA)GCTTTTTGCAGCAAAAAATTACTG (SEQ I D NO: 56) cm44: (TTA) CTG C A A A A A AG G G A A A A AC A AG G G (SEQ I D NO: 57) cm45: (TTA)CTACTTCTGAGTAAGCTTGGAGGC (SEQ ID NO: 58) cm46: (TTT)ACTTAACAGTTGCAGTTATTTTGG (SEQ I D NO: 59) cm47: (TTT)TG GGGGAGGG GTCTTTG GTTTTTT (SEQ I D NO: 60) cm48: (TTT)GGTTTTTTGAAACATTGAAAGCCT (SEQ ID NO: 61) cm49: (TTT)TTTGAAACATTGAAAGCCTTTACA (SEQ I D NO: 62) cm50: (TTT)CCTGTGTGTCTGCACCAGAGGCTT (SEQ ID NO: 63) cm51: (TTT)CATAGTAGAAAATGTATACATGCT (SEQ I D NO: 64) cm52: (TTT)CTAAATCCAGCCTTTCTTTCCACT (SEQ I D NO: 65) cm53: (TTT) CTTTCC ACTG C AC A ATCCTCTC AT (SEQ I D NO: 66) cm54: (TTT)CCACTGCACAATCCTCTCATGAAT (SEQ I D NO: 67) cm55: (TTT) G C A A A ATCCTTTTTTCT AG C A A AT (SEQ ID NO: 68) cm56: (TTT)TTTCTAG CAAATACTC AG AG CAG C (SEQ I D NO: 69) cm57: (TTT) CT AG CAAATACTC AG AG CAG CTT A (SEQ ID NO: 70) cm58: (TTT)TCTCAGGTAGGCCTTTGGTCTAAA (SEQ ID NO: 71) cm59: (TTT)GGTCTAAAATCTATCTGCCTTACA (SEQ ID NO: 72) cm60: (TTT)TGTTTTGGTGTTTTCTCTCTAAAT (SEQ ID NO: 73) cm61: (TTT)TCTCTCTAAATTAACTTTTACACT (SEQ ID NO: 74) cm62: (TTT)TACATCCTCAAATACAACCATAAA (SEQ I D NO: 75) cm63: (TTT)AATCTTTCTAATGGCATATTAACA (SEQ I D NO: 76) cm64: (TTT) CT A ATG G C ATATTA AC ATTT A ATG (SEQ I D NO: 77) cm65: (TTT)AATGACTTTCCCCCACAGAGATCA (SEQ ID NO: 78) cm66: (TTT)GCCACTGTCTATTGGCCCCTTGAA (SEQ ID NO: 79) cm67: (TTT)TTTG G AATGTTTAATACAATG CAT (SEQ I D NO: 80) cm68: (TTT)TTGGAATGTTTAATACAATGCATT (SEQ I D NO: 81) cm69: (TTT)TGGAATGTTTAATACAATGCATTT (SEQ I D NO: 82) cm70: (TTT)AATACAATGCATTTTAGAAAGTCA (SEQ ID NO: 83) cm71: (TTT)TAGAAAGTCATAAATAACAGTGTC (SEQ I D NO: 84) cm72: (TTT)GAGGCAGCAAGCAATGAATCCAGG (SEQ ID NO: 85) cm73: (TTT)TATCAAGCAAGAAATTAAACCTTT (SEQ ID NO: 86) cm74: (TTT)ATCAAGCAAGAAATTAAACCTTTC (SEQ ID NO: 87) cm75: (TTT)CAACTAACATT TCTTCTCTGGTCA (SEQ ID NO: 88) cm76: (TTT) GTTTG G CTG CT AC AGTATC A AC AG (SEQ I D NO: 89) cm77: (TTT) G G CTG CTAC AGT ATC A AC AG CCTG (SEQ ID NO: 90) cm78: (TTT)TTTG ATTTTTG CT ATCTG C A A A A A (SEQ ID NO: 91) cm79: (TTT)TTGATTTTTGCTATCTGCAAAAAT (SEQ ID NO: 92) cm80: (TTT)TG ATTTTTG CT ATCTG C A A A A ATT (SEQ ID NO: 93) cm81: (TTT)G ATTTTTG CT ATCTG CAAAAATTT (SEQ ID NO: 94) cm82: (TTT)TTG CT ATCTG C A A A A ATTTG G G C A (SEQ I D NO: 95) cm83: (TTT) G CT ATCTG C A A A A ATTTG G G C ATT (SEQ I D NO: 96) cm84: (TTT)GGGCATTATAATAGTGTTTTTCAT (SEQ I D NO: 97) cm85: (TTT)TCATGATGGTTAAAGTGATTTGGC (SEQ I D NO: 98) cm86: (TTT)GGCTGATCCTTTTTTTCACATTTT (SEQ ID NO: 99) cm87: (TTT)TTTTCAC ATTTTTTG CATTG CTGT (SEQ ID NO: 100) cm88: (TTT)TTTCACATTTTTTGCATTGCTGTG (SEQ ID NO: 101) cm89: (TTT)TTC AC ATTTTTTG CATTG CTGTG G (SEQ ID NO: 102) cm90: (TTT)TTC AC ATTTTTTG CATTG CTGTG G (SEQ ID NO: 103) cm91: (TTT)TC AC ATTTTTTG CATTG CTGTG G G (SEQ ID NO: 104) cm92: (TTT) C AC ATTTTTTG CATTG CTGTG G GT (SEQ ID NO: 105) cm93: (TTT)TTTG CATTG CTGTG GGTTTTCCTG (SEQ ID NO: 106) cm94: (TTT)TTGCATTGCTGTGGGTTTTCCTGA (SEQ ID NO: 107) cm95: (TTT)TG CATTG CTGTG GGTTTTCCTG AA (SEQ ID NO: 108) cm96: (TTT)GCATTGCTGTGGGTTTTCCTGAAA (SEQ ID NO: 109) cm97: (TTT)CCATGAAACCTGCTTAGTTTCTTC (SEQ ID NO: 110) cm98: (TTT)CTTCTGGTTCTTCTGGGTTAAAGT (SEQ ID NO: 111) cm99: (TTT)CTTCCACTACTGCATATGGCTGTC (SEQ ID NO: 112) cmlOO: (TTT)ACAAATTAAAAAACTAAAGGTACA (SEQ ID NO: 113) cmlOl: (TTT)TTG AC AGTAGTTATTA ATTG CTG A (SEQ ID NO: 114) cml02: (TTT)TGACAGTAGTTATTAATTGCTGAC (SEQ ID NO: 115) cml03: (TTT) G AC AGTAGTTATTA ATTG CTG AC A (SEQ ID NO: 116) cml04: (TTT)TTCCATAAGTTTCTTATATAAAAT (SEQ ID NO: 117) cml05: (TTT)TCCATAAGTTTCTTATATAAAATT (SEQ ID NO: 118) cml06: (TTT)CCATAAGTTTCTTATATAAAATTT (SEQ ID NO: 119) cml07: (TTT) CTT ATATA A A ATTTG AG CTTTTTC (SEQ ID NO: 120) cml08: (TTT)TTCTTT AGTG GT ATAC AC AG C A A A (SEQ ID NO: 121) cml09: (TTT)TCTTT AGTG GT ATAC AC AG C A A A A (SEQ ID NO: 122) cmllO: (TTT) CTTTAGTG GTAT AC AC AG C A A A AG (SEQ ID NO: 123) cmlll: (TTT)AGTGGTATACACAGCAAAAGAAGC (SEQ ID NO: 124) cmll2: (TTT)AGGGTCTTCTACCTTTTTTTTCTT (SEQ ID NO: 125) cmll3: (TTT)TTTTTCTTTTTAG GTGGGGTAGAG (SEQ ID NO: 126) cmll4: (TTT)TTTTCTTTTTAGGTGGGGTAGAGT (SEQ ID NO: 127) cmll5: (TTT)TTTCTTTTTAGGTGGGGTAGAGTG (SEQ ID NO: 128) cmll6: (TTT)TTCTTTTT AG GTGGGGTAGAGTGT (SEQ ID NO: 129) cmll7: (TTT)TCTTTTTAGGTGGGGTAGAGTGTT (SEQ ID NO: 130) cmll8: (TTT)CTTTTTAGGTGGGGTAGAGTGTTG (SEQ ID NO: 131) cmll9: (TTT)TC ATC ATC ACTG G C A A AC ATTTCT (SEQ ID NO: 132) cml20: (TTT) CATC ATC ACTG G C A A AC ATTTCTT (SEQ ID NO: 133) cml21: (TTT)ATTGTAAAAAACAAAATGCCCTGC (SEQ ID NO: 134) cml22: (TTT)AGATCCCTGTAGGGGGTGTCTCCA (SEQ ID NO: 135) cml23: (TTT)CTCCCAGCAATGAAGAGCTTCTTG (SEQ ID NO: 136) cml24: (TTT)TCTGTTTCTATGCCTTAATTTTAG (SEQ ID NO: 137) cml25: (TTT)T AG C ATG C AC ATTA A AC AG G G G C A (SEQ ID NO: 138) cml26: (TTT)TACACCTTGTTCCATTTTTTTATA (SEQ ID NO: 139) cml27: (TTT)ACACCTTGTTCCATTTTTTTATAT (SEQ ID NO: 140) cml28: (TTT)TTTATATAAAAAATTCATTCTCTT (SEQ ID NO: 141) cml29: (TTT) G C ATTTTTTC AG AT A AG CTTTTCT (SEQ ID NO: 142) cml30: (TTT)TTTC AG ATAAG CTTTTCTC ATG AC (SEQ ID NO: 143) cml31: (TTT)TTCAGATAAGCTTTTCTCATGACA (SEQ ID NO: 144) cml32: (TTT)TCAGATAAGCTTTTCTCATGACAG (SEQ ID NO: 145) cml33: (TTT) C AG AT A AG CTTTTCTC ATG AC AG G (SEQ ID NO: 146) cml34: (TTT)TCTCATG ACAG G AATGTTCCCCC A (SEQ ID NO: 147) cml35: (TTT)GTCCATTTTAGCTTTTTGCAGCAA (SEQ ID NO: 148) cml36: (TTT)T AG CTTTTTG C AG C A A A A A ATTAC (SEQ ID NO: 149) cml37: (TTT) AG CTTTTTG CAGCAAAAAATTACT (SEQ ID NO: 150) cml38: (TTT)TG C AG C A A A A A ATTACTG C A A A A A (SEQ ID NO: 151) cml39: (TTT) G C AG C A A A A A ATT ACTG C A A A A A A (SEQ ID NO: 152) cml40: (TTT)CCCTGGCCTCCTAAAAAGCCTCCA (SEQ ID NO: 153) cml41: (TTC)CTGTGTGTCTGCACCAGAGGCTTC (SEQ ID NO: 154) cml42: (TTC)TGAGACCTGGGA AAAGCATTGTGA (SEQ ID NO: 155) cml43: (TTC)TG CTTC AG A ATCTTCCTCTCTAG G (SEQ ID NO: 156) cml44: (TTC)AGAATCTTCCTCTCTAGGAAAGTC (SEQ ID NO: 157) cml45: (TTC)CTCTCTAGGAAAGTCAAGAATGGG (SEQ ID NO: 158) cml46: (TTC)TTTCCACTGCACAATCCTCTCATG (SEQ ID NO: 159) cml47: (TTC)TAGC AAATACTCAG AG CAG CTTAG (SEQ ID NO: 160) cml48: (TTC)TC AG GT AG G CCTTTG GTCT A A A AT (SEQ ID NO: 161) cml49: (TTC)T AG G C ACTG A ATATTC ATTC ATG G (SEQ ID NO: 162) cml50: (TTC) ATTC ATG GTTACAATTCCAG GTGG (SEQ ID NO: 163) cml51: (TTC)ATGGTTACAATTCCAGGTGGAAAC (SEQ ID NO: 164) cml52: (TTC)CAGGTGGAAACACCTGTGTTCTTT (SEQ ID NO: 165) cml53: (TTC)TTTTGTTTTGGTGTTTTCTCTCTA (SEQ ID NO: 166 cml54: (TTC)TCTCTAAATTAACTTTTACACTTC (SEQ ID NO: 167) cml55: (TTC)CATCTAAGTAATCTCTTAAGCAAT (SEQ ID NO: 168) cml56: (TTC)AAAGTTTAATCTTTCTAATGGCAT (SEQ ID NO: 169) cml57: (TTC)AAAGTTTAATCTTTCTAATGGCAT (SEQ ID NO: 170) cml58: (TTC)T A ATG G C ATATTA AC ATTT A ATG A (SEQ ID NO: 171) cml59: (TTC)CCCCACAGAGATCAAGTAAAGCTG (SEQ ID NO: 172) cml60: (TTC)AACTAACATTTCTTCTCTGGTCAT (SEQ ID NO: 173) cml61: (TTC)TCTGGTCATGTGGATGCTGTCAAC (SEQ ID NO: 174) cml62: (TTC)ATGATGGTTAAAGTGATTTGGCTG (SEQ ID NO: 175) cml63: (TTC)CTGAAAGTCTAAGTACATGCCCAT (SEQ ID NO: 176) cml64: (TTC)CATGAAACCTGCTTAGTTTCTTCT (SEQ ID NO: 177) cml65: (TTC)TTCTG GTTCTTCTGG GTTAAAGTC (SEQ ID NO: 178) cml66: (TTC)TGGTTCTTCTGGGTTAAAGTCATG (SEQ ID NO: 179) cml67: (TTC)TTCTG GGTTAAAGTC ATG CTCCTT (SEQ ID NO: 180) cml68: (TTC)TGGGTTAAAGTCATGCTCCTTAA (SEQ ID NO: 181) cml69: (TTC) C ACT ACTG CAT ATG G CTGTCT AC A (SEQ ID NO: 182) cml70: (TTC)ACACCTTTACAAATTAAAAAACTA (SEQ ID NO: 183) cml71: (TTC)CATAAGTTTCTTATATAAAATTTG (SEQ ID NO: 184) cml72: (TTC)TTATATAAAATTTG AG CTTTTTCT (SEQ ID NO: 185) cml73: (TTC)TATTACTAAACACAGCTTGACTGA (SEQ ID NO: 186) cml74: TTC)TACCTTTTTTTTCTTTTTAGGTGG (SEQ ID NO: 187) cml75: TTC)TTTTTAGGTGGGGTAGAGTGTTGG (SEQ ID NO: 188) cml76: TTC)TTTTTAGGTGGGGTAGAGTGTTGG (SEQ ID NO: 189) cml77: TTC)ATCATCACTGGCAAACATTTCTTC (SEQ ID NO: 190) cml78: TTC)ATCCCACTTCTCATTAAATGTATT (SEQ ID NO: 191) cml79: TTC)CACCAGGATTCCCATTCATCTGTT (SEQ ID NO: 192) cml80: TTC)CATTCATCTGTTCCATAGGTTGG (SEQ ID NO: 193) cml81: TTC)ATCTGTTCCATAGGTTGGCACCTA (SEQ ID NO: 194) cml82: TTC)CATAGGTTGGCACCTAAAAAAAAA (SEQ ID NO: 195) cml83: TTC)TCCC AG C A ATG A AG AG CTTCTTG G (SEQ ID NO: 196) cml84: TTC)TTGGGTTAAGTCACACCCAAACCA (SEQ ID NO: 197) cml85: TTC)TTAAAA ATTTTCTGTTTCTATG CC (SEQ ID NO: 198) cml86: TTC)TGTTTCTATGCCTTAATTTTAGCA (SEQ ID NO: 199) cml87: TTC)CTTGCAATAAAGGGTATCAGAATT (SEQ ID NO: 200) cml88: TTC)CATGTACCAAAATCAGGCTGATGA (SEQ ID NO: 201) cml89: TTC)CATTTTTTTATATAAAAAATTCAT (SEQ ID NO: 202) cml90: TTC)ATTCTCTTCATCTTGTCTTCGTCC (SEQ ID NO: 203) cml91: TTC)TCTTCATCTTGTCTTCGTCCCCAC (SEQ ID NO: 204) cml92: TTC)ATCTTGTCTTCGTCCCCACCTTTA (SEQ ID NO: 205) cml93: TTC)GTCCCCACCTTTATCAGGGTGGAG (SEQ ID NO: 206) cml94: TTC)TTTGCATTTTTTCAGATAAGCTTT (SEQ ID NO: 207) cml95: TTC)AGATAAGCTTTTCTCATGACAGGA (SEQ ID NO: 208) cml96: (TTC)TCATGACAGGAATGTTCCCCCATG (SEQ I D NO: 209) cml97: (TTC)CCCCATGCAGACCTATCAAGGCCT (SEQ ID NO: 210) cml98: (TTC)CTCCCTATTCAGCACTTTGTCCAT (SEQ I D NO: 211) cml99: (TTC)AGCACTTTGTCCATTTTAGCTTTT (SEQ I D NO: 212) cm200: (TTC)CCTGGCCTCCTAAAAAGCCTCCAC (SEQ I D NO: 213) cm201: (TTC)TGAGTAAGCTTGGAGGCGGAGGCG (SEQ ID NO: 214) cm202: (TTG)CAGTTATTTTGGGGGAGGGGTCTT (SEQ I D NO: 215) cm203 : (TTG)GGGGAGGGGTCTTTGGTTTTTTGA (SEQ I D NO: 216) cm204: (TTG)GTTTTTTGAAACATTGAAAGCCTT (SEQ I D NO: 217) cm205 : (TTG ) A AACATTG AAAG CCTTTAC AG ATG (SEQ I D NO: 218) cm206: (TTG ) A A AG CCTTTAC AG ATGTG A A A AGT (SEQ I D NO: 219) cm207: (TTG)TGATTGTGATTCAGTGCTTGATCC (SEQ I D NO: 220) cm208: (TTG)TGATTCAGTGCTTGATCCATGTCC (SEQ ID NO: 221) cm209: (TTG )ATCCATGTCCAG AGTCTTCTGCTT (SEQ ID NO: 222) cm210: (TTG)CAAAATCC I I I I I I CTAGCAAATA (SEQ ID NO: 223) cm211: (TTG)GTGTTTTCTCTCTAAATTAACTTT (SEQ I D NO: 224) cm212: (TTG)CCACTGTCTATTGGCCCCTTGAAT (SEQ I D NO: 225) cm213 : (TTG )G CCCCTTG AATAG CC AGTACCTTT (SEQ ID NO: 226) cm214: (TTG ) AATAG CC AGT ACCTTTTTTTTG G A (SEQ I D NO: 227) cm215 : (TTG)GAATGTTTAATACAATGCATTTTA (SEQ I D NO: 228) cm216: (TTG ) AG G C AG C A AG C A ATG A ATCC AG G C (SEQ I D NO: 229) cm217: (TTG)CCATGTGCCCCAAAAATTAAGTCC (SEQ I D NO: 230) cm218: (TTG )TTTG G CTG CT AC AGTATC A AC AG C (SEQ ID NO: 231) cm219: (TTG )G CTG CTAC AGT ATC A AC AG CCTG C (SEQ I D NO: 232) cm220: (TTG ) ATTTTTG CT ATCTG C A A A A ATTTG (SEQ I D NO: 233) cm221: (TTG )CT ATCTG C A A A A ATTTG G G C ATT A (SEQ I D NO: 234) cm222: (TTG )G G CATTATAATAGTGTTTTTCATG (SEQ ID NO: 235) cm223 : (TTG)GCTGATCCTTTTTTTCACATTTTT (SEQ I D NO: 236) cm224: (TTG)CTGTGGGTTTTCCTGAAAGTCTAA (SEQ I D NO: 237) cm225 : (TTG)GTTTCCAAGGCATACTGTGTAACT (SEQ I D NO: 238) cm226: (TTG)ACAGTAGTTATTAATTGCTGACAC (SEQ I D NO: 239) cm227: (TTG)CTGACACTCTATGTCTATGTGGTG (SEQ ID NO: 240) cm228: (TTG ) ACTG AG G A ATG C ATG C AG ATCTAC (SEQ I D NO: 241) cm229: (TTG)GGATCCTGTGTTTTCATCATCACT (SEQ ID NO: 242) cm230: (TTG )G GTTAAGTCAC ACCCAA ACCATTG (SEQ I D NO: 243) cm231: (TTG )TCTG A AG C A ATC A A AG C A ATAG C A (SEQ ID NO: 244) cm232: (TTG )C A ATA A AG G GTATC AG A ATT AG G A (SEQ I D NO: 245) cm233 : (TTG)TTCCATTTTTTTATATAAAAAATT (SEQ ID NO: 246) cm234: (TTG)TCTTCGTCCCCACCTTTATCAGGG (SEQ ID NO: 247) cm235 : (TTG)CATTTTTTCAGATAAGCTTTTCTC (SEQ ID NO: 248) cm236: (TTG )C AG CAAAAAATTACTG CAAAAAAG (SEQ I D NO: 249) [000109] The invention has been described in an illustrative manner, and it is to be understood that the terminology that has been used is intended to be in the nature of words of description rather than of limitation. Obviously, many modifications and variations of the present invention are possible in light of the above teachings. It is, therefore, to be understood that within the scope of the appended claims, the invention can be practiced otherwise than as specifically described.

REFERENCES:

Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, MJA Wood. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nature Biotechnol. 2011, 29: 341-345.

Andrei G, Snoeck R, Vandeputte M, De Clercq E. Activities of various compounds against murine and primate polyomaviruses. Antimicrob Agents Chemother. 1997; 41: 587-593.

Bag AK, Cure JK, Chapman PR, Roberson GH, Shah R. JC virus infection of the brain. ANJR 2010, 31: 1564-1576.

Bayliss J, Karasoulos T CAMcLean. Immunosuppression Increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy. J. Infections Diseases, 2012, DOI: 10.1093/infdis/jis668.

Berger JR. The clinical features of PML. Cleve Clin J Med. 2011; 78 Suppl2: S8-12.

Bhaya D, Davison M, Barrangou R. CRISPR-Cas systems in bacteria and archaea: versatile small RNAs for adaptive defense and regulation. Annu Rev Genet. 2011; 45: 273-297.

Chalkley JJ, Berger JR. Progressive multifocal leukoencephalopathy in multiple sclerosis. Curr Neurol Neurosci Rep. 2013; 13: 408.

Chapagain ML, Sumibcay L, Gurjav U, Kaufusi PH, Kast RE, Nerurkar VR. Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol. 2008; 14: 448-454.

Clifford DB, Ances B, Costello C, Rosen-Schmidt S, Andersson M, Parks D, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011; 68: 1156-1164.

DeCaprio JA, Imperiale MJ, Major EO. Polyomaviruses. In: Fields Virology, 6th edition. Knipe DM and Howley PM (Eds). Philadelphia: Lippincott, Williams & Wilkins; 2013. pp. 1633-1661. Ding Q, Strong A, Patel KA, Ng SL, Gosis BS, Regan SN, Cowan CA, Rader DJ, Musunuru K. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ. Res. 2014, 115:488-492.

Doyle EL, Booher N., Standage DS, Voytas DF, Brendel VP, VanDyk, JK, Bogdanove AJ. (2012) TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction. Nucleic Acids Res. doi: 10.1093/nar/gks608.

Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306: 1380-1383.

Frisque RJ, Bream GL, Cannella MT. Human polyomavirus JC virus genome. J Virol. 1984; 51: 458-469.

Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013; 31: 397-405.

Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J. Neurovirol. 1998; 4: 451-456.

Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157: 1262-1278.

Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 2014; 111: 11461-11466.

Khalili K, White M K, Sawa H, Nagashima K, Safak M. The agnoprotein of polyomaviruses: a multifunctional auxiliary protein. J Cell Physiol. 2005; 204: 1-7.

Kooijmans SAA, Vader P, Dommelen SM, van Solinge WW, Raymond M Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int. J. Nanomed. 2012, 7: 1525-1541.

Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 2014, 157: 1262-1278.

Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, Bobbitt K, Rempel SA, Hasselbach L, Mikkelsen T, Slavin S, Brodie C. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013, 4:346-61.

Lee Y, Andaloussi SE, Wood MJA. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Human Molecular Genetics 212, doi:10,1093/hmg/dds317.

Mali P, Esvelt KM, Church GM. Cas9 as a versatile tool for engineering biology. Nat Methods 2013; 10:957-963.

Marcus ME, and Leonard JN. FedExosomes: Engineering therapeutic biological nanoparticles that truly deliver. Pharmaceuticals 2103, 6: 659-680.

Miller JC, Tan S, Qiao G, Barlow K, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ, Dulay GP, Hua KL, Ankoudinova I, Cost GJ, Urnov FD, Zhang HS, Holmes MC, Zhang L, Gregory PD, Rebar EJ. A TALE nuclease architecture for efficient genome editing. Nature Biotechnology 2011: 29: 143 -150.

Nagayama S, Gondo Y, Araya S, Minato N, Fujita-Nakata M, Kaito M, et al. Progressive multifocal leukoencephalopathy developed 26 years after renal transplantation. Clin Neurol Neurosurg. 2013; 115: 1482-1484.

San Sebastian W, Samaranch L, Kells AP, Forsayeth, Bankiewicz KS. Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 10:498-510.

Sander JD, Maeder M., Reyon D, Voytas DF, Joung JK, Dobbs D. (2010) ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. Nucleic Acids Research, 38:W462-468.

Saribas AS, Ozdemir A, Lam C, Safak M. JC virus-induced progressive multifocal leukoencephalopathy. Future Virol 2010, 7: 313-323. Schwab N, Ulzheimer JC, Fox J, Schneider-Hohendorf T, Kieseier BC, Monoranu CM, et al. Fatal progressive multifocal leukoencephalopathy associated with efalizumab therapy: insights into the role of leukointegrin aLb2 in JC virus control. Neurology 2012; 78: 458-467.

Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Communication and Signaling 2013, 11:88 (http://www.biosignaling.eom/content/ll/l/88).

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Feng Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Published online 1 December 2015 [DOI:10.1126/science.aad5227]

Sun W, Jiang T, Yue Lu Y, Reiff M, Mo R, Zhen Gu Z. Cocoon-like self-degradable DNA nanoclew for anticancer drug delivery. J. Am. Chem. Soc. 2014, 136:14722-14725.

Sun W, Ji W, Hall JM, Hu Q, Wang C, Beisel CL, Gu Z. Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. 2015: 12029-12033.

Tavazzi E, White MK, Khalili K. Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol. 2012; 22:2.

Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD: Genome editing with engineered zinc finger nucleases. Nat Rev Genet 2010, ll(9):636-646.

Waggoner J, Martinu T, MD, Palmer, SM. Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant: A case report. J. Heart Lung Transplant 2009, 28: 395-398.

White MK, Khalili K. Polyomaviruses and human cancer: molecular mechanisms underlying patterns of tumorigenesis. Virology 2004; 324: 1-16.

White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy— revisited. J Infect Dis. 2011; 203: 578-586. Wollebo HS, Bellizzi A, Kaminski R, Hu W, White MK, Khalili K. CRISPR/Cas9 system as an agent for eliminating polyomavirus JC infection. PLoS ONE 2015, 10(9): e0136046. doi:10.1371/journal.pone.0136046.

Zetsche B, Gootenberg JS., Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F, Cpfl Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. Cell 163, 1-13 October 22, 2015.